Sienna Biopharmaceuticals, Inc.
30699 Russell Ranch Road
Suite 140
Westlake Village, CA 91362
United States
818-629-2256
https://www.siennabio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 13
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Frederick C. Beddingfield III, M.D., Ph.D. | CEO, President & Director | 762k | 無 | 1965 |
| Mr. Timothy K. Andrews Esq. | General Counsel & Corporate Secretary | 446.1k | 無 | 1979 |
| Dr. Silvio Traversa BSc Ph.D. | Chief Scientific Officer | 無 | 無 | 1970 |
| Mr. Sean Andrews | Vice President of Investor Relations | 無 | 無 | 無 |
| Mr. Theodore Schwartz | Head of Global Strategic Marketing | 無 | 無 | 1961 |
| Mr. Michael Attar | VP & Head of Corporate Development | 無 | 無 | 無 |
| Dr. David E. I. Pyott M.A., M.B.A., M.D. | Strategic Advisor to the Board and CEO | 無 | 無 | 1953 |
描述
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.
公司管治
截至 無 止，Sienna Biopharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
